A Long-Term, Open-Label Extension Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
Latest Information Update: 17 Nov 2025
At a glance
- Drugs Bivamelagon (Primary)
- Indications Hypothalamic disorders; Obesity
- Focus Adverse reactions
- Sponsors Rhythm
Most Recent Events
- 13 Nov 2025 Status changed from not yet recruiting to recruiting.
- 15 Sep 2025 New trial record